WO2003048334A3 - Immunocytokines with modulated selectivity - Google Patents

Immunocytokines with modulated selectivity Download PDF

Info

Publication number
WO2003048334A3
WO2003048334A3 PCT/US2002/038780 US0238780W WO03048334A3 WO 2003048334 A3 WO2003048334 A3 WO 2003048334A3 US 0238780 W US0238780 W US 0238780W WO 03048334 A3 WO03048334 A3 WO 03048334A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
immunocytokines
cytokine
bind
therapeutic index
Prior art date
Application number
PCT/US2002/038780
Other languages
French (fr)
Other versions
WO2003048334A2 (en
Inventor
Stephen D Gillies
Original Assignee
Emd Lexigen Res Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003549513A priority Critical patent/JP4795640B2/en
Application filed by Emd Lexigen Res Ct Corp filed Critical Emd Lexigen Res Ct Corp
Priority to BR0214650-9A priority patent/BR0214650A/en
Priority to AT02792325T priority patent/ATE542137T1/en
Priority to EP02792325A priority patent/EP1454138B1/en
Priority to AU2002357784A priority patent/AU2002357784B2/en
Priority to ES02792325T priority patent/ES2381025T3/en
Priority to DK02792325.9T priority patent/DK1454138T3/en
Priority to MXPA04005266A priority patent/MXPA04005266A/en
Priority to CA2469151A priority patent/CA2469151C/en
Priority to HU0402541A priority patent/HU229098B1/en
Publication of WO2003048334A2 publication Critical patent/WO2003048334A2/en
Publication of WO2003048334A3 publication Critical patent/WO2003048334A3/en
Priority to ZA2004/05247A priority patent/ZA200405247B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The invention provides cytokine fusion proteins, with an increased therapeutic index and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
PCT/US2002/038780 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity WO2003048334A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES02792325T ES2381025T3 (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity
BR0214650-9A BR0214650A (en) 2001-12-04 2002-12-04 Modulated selectivity immunocytokines
AT02792325T ATE542137T1 (en) 2001-12-04 2002-12-04 IMMUNOCYTOKINE WITH MODULATED SELECTIVITY
EP02792325A EP1454138B1 (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity
AU2002357784A AU2002357784B2 (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity
JP2003549513A JP4795640B2 (en) 2001-12-04 2002-12-04 Immune cytokines with regulated selectivity
DK02792325.9T DK1454138T3 (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity
HU0402541A HU229098B1 (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity
CA2469151A CA2469151C (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity
MXPA04005266A MXPA04005266A (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity.
ZA2004/05247A ZA200405247B (en) 2001-12-04 2004-07-01 Immunocytokines with modulated selectivity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33711301P 2001-12-04 2001-12-04
US60/337,113 2001-12-04
US37196602P 2002-04-12 2002-04-12
US60/371,966 2002-04-12

Publications (2)

Publication Number Publication Date
WO2003048334A2 WO2003048334A2 (en) 2003-06-12
WO2003048334A3 true WO2003048334A3 (en) 2003-09-04

Family

ID=26990541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038780 WO2003048334A2 (en) 2001-12-04 2002-12-04 Immunocytokines with modulated selectivity

Country Status (18)

Country Link
US (3) US7186804B2 (en)
EP (2) EP1454138B1 (en)
JP (1) JP4795640B2 (en)
KR (1) KR100988180B1 (en)
CN (1) CN100390282C (en)
AT (1) ATE542137T1 (en)
AU (1) AU2002357784B2 (en)
BR (1) BR0214650A (en)
CA (1) CA2469151C (en)
DK (1) DK1454138T3 (en)
ES (1) ES2381025T3 (en)
HU (1) HU229098B1 (en)
MX (1) MXPA04005266A (en)
PL (1) PL206975B1 (en)
PT (1) PT1454138E (en)
RU (1) RU2312677C9 (en)
WO (1) WO2003048334A2 (en)
ZA (1) ZA200405247B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site
US11851467B2 (en) 2016-12-22 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11958893B2 (en) 2021-07-21 2024-04-16 Cue Biopharma, Inc. Methods for modulating an immune response

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267215T1 (en) 1997-12-08 2004-06-15 Lexigen Pharm Corp HETERODIMARY FUSION PROTEINS FOR USE FOR TARGETED IMMUNTHERAPY AND GENERAL IMMUNE EXCITATION
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
PL343462A1 (en) * 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
ES2288967T3 (en) * 2000-06-29 2008-02-01 Merck Patent Gmbh REINFORCEMENT OF IMMUNE ANSWERS MEDIATED BY THE ANTIBODY-CYTOKIN FUSION PROTEIN THROUGH THE TREATMENT COMBINED BY AGENTS THAT IMPROVE THE INCORPORATION OF IMMUNOCITOQUINE.
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (en) 2001-05-03 2004-10-05 Merck Patent Gmbh Recombinant tumor specific antibody and use
ES2381025T3 (en) 2001-12-04 2012-05-22 Merck Patent Gmbh Immunocytokines with modulated selectivity
ES2346205T3 (en) 2002-12-17 2010-10-13 Merck Patent Gmbh HUMANIZED ANTIBODY (H14.18) OF ANTIBODY 14.18 OF MOUSE THAT LINKS TO GD2 AND ITS FUSION WITH IL-2.
US7541439B2 (en) * 2003-06-26 2009-06-02 Merck Patent Gmbh Thrombopoietin proteins with improved properties
DK1648931T3 (en) 2003-07-21 2011-03-07 Transgene Sa Multifunctional cytokines
DE602004031341D1 (en) 2003-07-21 2011-03-24 Transgene Sa MULTIFUNCTIONAL CYTOKINE
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005063820A2 (en) 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
KR20060124656A (en) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DE602005020837D1 (en) * 2004-12-09 2010-06-02 Merck Patent Gmbh IL-7 VARIANTS WITH REDUCED IMMUNOGENITY
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
PT2270050E (en) 2005-12-30 2013-09-12 Merck Patent Gmbh Anti-cd19 antibodies with reduced immunogenicity
CA2635618C (en) * 2005-12-30 2015-10-06 Merck Patent Gesellschaft Mit Beschraekter Haftung Interleukin-12p40 variants with improved stability
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DE102008023820A1 (en) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
CN101343323B (en) * 2008-08-29 2011-02-16 浙江大学 Anti-interleukins-8 antibody
EP2337579A1 (en) * 2008-10-21 2011-06-29 Merck Patent GmbH Cancer treatments with radiation and immunocytokines
WO2010077831A1 (en) * 2008-12-16 2010-07-08 Tod Lauerman Targeted cytokine for treatment of diseases
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
CU23734A1 (en) 2009-11-27 2011-11-15 Centro Inmunologia Molecular IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
EP3971206A1 (en) * 2011-02-10 2022-03-23 Roche Glycart AG Mutant interleukin-2 polypeptides
BR112013019083A2 (en) 2011-02-10 2017-04-04 Roche Glycart Ag combination of (a) an immunoconjugate, pharmaceutical composition, use of (a) an immunoconjugate, method of treating a disease in an individual, method of stimulating cellular function in an individual, and kit for treating a disease.
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2734232B1 (en) * 2011-07-19 2017-11-01 Philogen S.p.A. Sequential anti-ctla4 and targeted il-2 therapy
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CA2872195A1 (en) 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2013359907B2 (en) 2012-12-11 2018-01-18 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
CN105324124A (en) 2013-04-19 2016-02-10 赛腾制药 Cytokine derived treatment with reduced vascular leak syndrome
DK3299466T3 (en) * 2013-07-18 2019-11-18 Vib Vzw FUSOKINES INVOLVING CYTOKINES WITH POWERFULLY REDUCED RECEPTOR BINDING EFFINITIES
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
CA2931114A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3134102B1 (en) * 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191602A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
WO2015191610A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
WO2015191590A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2015191615A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
WO2015191617A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
PT3172227T (en) * 2014-07-21 2019-12-06 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201700629TA (en) * 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3233192B1 (en) 2014-12-15 2021-04-14 Washington University Compositions and methods for targeted cytokine delivery
TWI691512B (en) 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Fc fusion high affinity IgE receptor alpha chain
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
CN106699888B (en) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 PD-1 antibody and preparation method and application thereof
JP7299021B2 (en) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Biorelevant Orthogonal Cytokine/Receptor Pairs
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP7325186B2 (en) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Type II anti-CD20 antibody for reducing the formation of anti-drug antibodies
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3011374A1 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
WO2017139570A1 (en) 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
BR112018073606A2 (en) 2016-05-18 2019-02-26 Cue Biopharma, Inc. T-cell modulating multimeric polypeptides and methods of using them
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109952370B (en) 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 Methods for producing immunoconjugates
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
SG11201908391XA (en) * 2017-03-15 2019-10-30 Cue Biopharma Inc Methods for modulating an immune response
CN110392692B (en) 2017-04-03 2023-07-21 豪夫迈·罗氏有限公司 Immunoconjugates of anti-PD-1 antibodies with mutant IL-2 or with IL-15
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CN110505883A (en) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 Proleulzin immunoconjugates used in method for treating cancer, CD40 agonist, and optionally PD-1 axis binding antagonists
CN110662762A (en) * 2017-05-24 2020-01-07 诺华股份有限公司 Antibody cytokine transplantation proteins and methods for treating cancer
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
WO2018215938A1 (en) * 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
JOP20190271A1 (en) * 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
EP3641814A4 (en) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
CN111094330A (en) 2017-07-03 2020-05-01 转矩医疗股份有限公司 Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
US20200181220A1 (en) * 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
IL297361B1 (en) * 2017-09-07 2024-03-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2018337686B2 (en) * 2017-09-21 2023-04-20 Merck Patent Gmbh Fusion protein comprising an FGF-18 moiety
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US20200317787A1 (en) * 2017-12-26 2020-10-08 Nanjingjinsirui Science & Technology Biology Corp. Fusion protein dimer using antibody fc region as backbone and use thereof
AU2018394189B2 (en) 2017-12-27 2023-12-21 Kyowa Kirin Co., Ltd. IL-2 variant
CN111886241A (en) * 2018-01-09 2020-11-03 库尔生物制药有限公司 Multimeric T cell modulating polypeptides and methods of use thereof
WO2019168791A2 (en) * 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells
CN108503714A (en) * 2018-04-10 2018-09-07 浙江科途医学科技有限公司 A kind of human interleukin 2 and anti-human signal transduction factor scfv fusion protein and its application
AU2019271148B2 (en) * 2018-05-14 2023-07-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019246404A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN112654633A (en) 2018-06-22 2021-04-13 科优基因公司 Cytokine-based bioactivatable agents and methods of use thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7289158B2 (en) 2018-08-06 2023-06-09 メディカイン、インコーポレイテッド IL-2 receptor binding compounds
AU2019343850A1 (en) * 2018-09-17 2020-06-25 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
MX2021003580A (en) * 2018-09-28 2021-10-13 Pf Medicament New immunocytokines for the treatment of cancer.
US20220056094A1 (en) * 2018-12-21 2022-02-24 Jiangsu Hengrui Medicine Co., Ltd. Human interleukin-2 variant or derivative thereof
JP2022515223A (en) 2018-12-21 2022-02-17 オーエスイー・イミュノセラピューティクス Bifunctional molecule for human PD-1
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
CN111944036A (en) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 Mutant protein for proliferating immune cells
CN111944008A (en) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 Method for mutating protein and obtained mutant protein
BR112021023345A2 (en) 2019-05-20 2022-02-01 Pandion Operations Inc Targeted immunotolerance in madcam
AU2020279534A1 (en) 2019-05-20 2021-11-11 Cytune Pharma IL-2/IL-15Rβy agonist dosing regimens for treating cancer or infectious diseases
CN114728040A (en) * 2019-06-14 2022-07-08 科优基因公司 Novel interleukin-2 variants and bifunctional fusion molecules thereof
EP3994169A1 (en) 2019-07-02 2022-05-11 F. Hoffmann-La Roche AG Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
JP7427287B2 (en) * 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド Dual IL-2R and IL-7R binding compounds
AU2020380296A1 (en) 2019-11-05 2022-06-16 Medikine Inc. IL-2RβγC binding compounds
IL293680B2 (en) 2019-12-13 2024-04-01 Synthekine Inc Il-2 orthologs and methods of use
WO2021127487A2 (en) * 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP2023514010A (en) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー Modified IL-2 polypeptides and uses thereof
EP4090674A4 (en) * 2020-01-14 2024-01-24 Synthekine Inc Biased il2 muteins methods and compositions
MX2022009302A (en) 2020-02-03 2022-11-16 Medikine Inc Il-7rî± binding compounds.
BR112022015002A2 (en) 2020-02-03 2022-12-06 Medikine Inc IL-7R-ALPHA/GAMMA/C LIGAND, COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF A DISEASE IN A PATIENT, AND NUCLEIC ACID
JP2023527690A (en) 2020-05-11 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with modified PBMC and immunoconjugate
MX2022013208A (en) 2020-05-12 2022-11-14 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof.
JP2023529981A (en) 2020-06-19 2023-07-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Immunostimulatory Fc domain binding molecules
US20230398185A1 (en) 2020-10-26 2023-12-14 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
IL302321A (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
AU2021393752A1 (en) 2020-12-04 2023-05-18 F. Hoffmann-La Roche Ag Ph-dependent mutant interleukin-2 polypeptides
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4314032A1 (en) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
EP4342983A1 (en) 2021-05-18 2024-03-27 Cells & Genes Biotech (Shanghai) Co., Ltd Method for modifying cell
TW202317623A (en) 2021-06-14 2023-05-01 美商再生元醫藥公司 Il2-based therapeutics and methods of use thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2023017191A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2023230594A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
US20230391844A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024068705A1 (en) 2022-09-29 2024-04-04 F. Hoffmann-La Roche Ag Protease-activated polypeptides
CN116041539B (en) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 IL-2 mutant immunoconjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2922685A (en) * 1957-11-12 1960-01-26 Brunswick Balke Collender Co Adjustable top desk
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (en) * 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3712985A1 (en) 1987-04-16 1988-11-03 Hoechst Ag BIFUNCTIONAL PROTEINS
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK173067B1 (en) 1986-06-27 1999-12-13 Univ Washington Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE122238T1 (en) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc BIFUNCTIONAL ANTIBODY CONSTRUCTIONS AND METHOD FOR SELECTIVE KILLING OF CELLS.
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
ES2054753T3 (en) 1987-09-02 1994-08-16 Ciba Geigy Ag CONJUGATES OF CYTOKINES WITH IMMUNOGLOBULINS.
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (en) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro SPECIFIC MONOCLONAL ANTIBODY FOR A SEQUENCE OF FIBRONETIN EXPRESSED IN TRANSFORMED HYBRID CELLS ACCORDING TO SUCH ANTIBODY AND USE OF THE MONOCLONAL ANTIBODY FOR THE DIAGNOSIS OF TUMORS
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE123065T1 (en) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd PROTEINS AND THEIR PRODUCTION.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ATE163675T1 (en) 1989-12-22 1998-03-15 Hoffmann La Roche CYTOTOXIC LYMPHOCYTE MATURATION FACTOR
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ATE173763T1 (en) 1991-08-30 1998-12-15 Hutchinson Fred Cancer Res HYBRID CYTOKINE
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
JP2597060B2 (en) * 1991-12-13 1997-04-02 富士通株式会社 Array disk device
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
ATE260971T1 (en) 1992-04-01 2004-03-15 Univ Rockefeller METHOD FOR THE IN VITRO CULTIVATION OF DENDRITIC PRECURSOR CELLS AND THEIR USE FOR IMMUNOGENIC PRODUCTION
DK0615451T3 (en) * 1992-05-26 2006-04-24 Immunex Corp Hitherto unknown cytokine that binds to CD30
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
DE4228839A1 (en) 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
DE69232604T2 (en) 1992-11-04 2002-11-07 City Of Hope Duarte ANTIBODY CONSTRUCTS
EP1757694A3 (en) * 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
JPH08509614A (en) * 1993-04-29 1996-10-15 アボツト・ラボラトリーズ Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
CN1057534C (en) 1993-08-17 2000-10-18 柯瑞英-艾格公司 Erythropoietin analogs
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
AU692865B2 (en) * 1994-04-26 1998-06-18 Children's Medical Center Corporation Angiostatin and method of use for inhibition of angiogenesis
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
PT706799E (en) 1994-09-16 2002-05-31 Merck Patent Gmbh IMUNOCONJUGADOS II
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
ES2225874T3 (en) * 1995-03-10 2005-03-16 Genentech, Inc. RECEIVER ACTIVATION THROUGH GAS.
US5719266A (en) * 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
WO1997002004A2 (en) * 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
US6406689B1 (en) * 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6008361A (en) * 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
CN1136197C (en) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 Novel pyridajinone derivatives
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ATE218143T1 (en) * 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0973550B1 (en) * 1997-04-11 2002-10-09 G.D. SEARLE & CO. Antagonistic anti-avb3 integrin antibodies
ATE267215T1 (en) * 1997-12-08 2004-06-15 Lexigen Pharm Corp HETERODIMARY FUSION PROTEINS FOR USE FOR TARGETED IMMUNTHERAPY AND GENERAL IMMUNE EXCITATION
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
PL343462A1 (en) 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP1071469A2 (en) * 1998-04-17 2001-01-31 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
WO1999054484A1 (en) * 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
WO1999058662A1 (en) 1998-05-14 1999-11-18 Merck Patent Gmbh Fused protein
DZ2788A1 (en) * 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
CA2339331C (en) * 1998-08-25 2011-03-01 Lexigen Pharmaceuticals Corporation Expression and export of angiogenesis inhibitors as immunofusins
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
KR20020007287A (en) * 1999-01-07 2002-01-26 추후보정 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
US7115261B1 (en) * 1999-02-12 2006-10-03 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
KR100922809B1 (en) 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 Compositions And Methods For Identifying Antigens Which Elicit An Immune Response
US6348192B1 (en) * 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
EP1187852B1 (en) * 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
CN1114617C (en) * 1999-07-19 2003-07-16 王革 Process for preparing recombined human interleukin-11 by use of hydroxylamine to cut fusion protein
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2001036489A2 (en) * 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
PT1257297E (en) * 2000-02-24 2006-12-29 Philogen Spa Compositions and methods for treatemnt of angiogenesis in pathological lesions
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
MXPA02011016A (en) * 2000-05-12 2004-03-16 Neose Technologies Inc In vitro.
ES2288967T3 (en) * 2000-06-29 2008-02-01 Merck Patent Gmbh REINFORCEMENT OF IMMUNE ANSWERS MEDIATED BY THE ANTIBODY-CYTOKIN FUSION PROTEIN THROUGH THE TREATMENT COMBINED BY AGENTS THAT IMPROVE THE INCORPORATION OF IMMUNOCITOQUINE.
JP2004525621A (en) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Bifunctional fusion protein having glucocerebrosidase activity
JP2004532620A (en) * 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Artificial proteins with reduced immunogenicity
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (en) 2001-05-03 2004-10-05 Merck Patent Gmbh Recombinant tumor specific antibody and use
EP1476180A4 (en) * 2001-08-13 2005-04-20 Univ Southern California Interleukin-2 mutants with reduced toxicity
ES2381025T3 (en) * 2001-12-04 2012-05-22 Merck Patent Gmbh Immunocytokines with modulated selectivity
ES2346205T3 (en) * 2002-12-17 2010-10-13 Merck Patent Gmbh HUMANIZED ANTIBODY (H14.18) OF ANTIBODY 14.18 OF MOUSE THAT LINKS TO GD2 AND ITS FUSION WITH IL-2.
US20050025573A1 (en) 2003-07-31 2005-02-03 Waldman John Jeffrey Liquid control structure
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005063820A2 (en) * 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
KR20060124656A (en) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DE602005020837D1 (en) * 2004-12-09 2010-06-02 Merck Patent Gmbh IL-7 VARIANTS WITH REDUCED IMMUNOGENITY
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR20080090484A (en) 2005-12-30 2008-10-08 메르크 파텐트 게엠베하 Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
PT2270050E (en) * 2005-12-30 2013-09-12 Merck Patent Gmbh Anti-cd19 antibodies with reduced immunogenicity
CA2635618C (en) * 2005-12-30 2015-10-06 Merck Patent Gesellschaft Mit Beschraekter Haftung Interleukin-12p40 variants with improved stability
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US9908376B2 (en) 2015-08-24 2018-03-06 Alireza Sedighpour Tire grip enhancing assembly
US11258202B2 (en) 2019-10-24 2022-02-22 Jonathon R. Weeks Secure outlet device and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site
US11851467B2 (en) 2016-12-22 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11958893B2 (en) 2021-07-21 2024-04-16 Cue Biopharma, Inc. Methods for modulating an immune response

Also Published As

Publication number Publication date
US20030166163A1 (en) 2003-09-04
KR100988180B1 (en) 2010-10-18
AU2002357784B2 (en) 2008-07-31
HUP0402541A2 (en) 2005-03-29
JP2005511707A (en) 2005-04-28
US7186804B2 (en) 2007-03-06
RU2312677C2 (en) 2007-12-20
EP1454138A4 (en) 2007-02-21
DK1454138T3 (en) 2012-02-13
BR0214650A (en) 2005-05-03
US7462350B2 (en) 2008-12-09
HUP0402541A3 (en) 2010-01-28
MXPA04005266A (en) 2004-10-11
US7888071B2 (en) 2011-02-15
EP1454138B1 (en) 2012-01-18
US20090098609A1 (en) 2009-04-16
CA2469151A1 (en) 2003-06-12
PT1454138E (en) 2012-03-28
ZA200405247B (en) 2005-08-31
CN100390282C (en) 2008-05-28
EP2354791A1 (en) 2011-08-10
US20070036752A1 (en) 2007-02-15
CN1599867A (en) 2005-03-23
PL206975B1 (en) 2010-10-29
EP1454138A2 (en) 2004-09-08
CA2469151C (en) 2013-08-13
PL369741A1 (en) 2005-05-02
JP4795640B2 (en) 2011-10-19
ATE542137T1 (en) 2012-02-15
KR20050044862A (en) 2005-05-13
HU229098B1 (en) 2013-07-29
RU2004119961A (en) 2005-04-20
AU2002357784A1 (en) 2003-06-17
ES2381025T3 (en) 2012-05-22
WO2003048334A2 (en) 2003-06-12
RU2312677C9 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2003048334A3 (en) Immunocytokines with modulated selectivity
EP2248892A3 (en) Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
AU3501197A (en) Human stem cell antigens, dna coding therefor and their use
CA2440094A1 (en) Structural reinforcement member and method of use therefor
AU7833698A (en) Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
EP1571216A3 (en) Phosphodiesterase 8A
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
WO2004083245A3 (en) Agent comprise an albumin-like first polypeptide bound to a second polypeptide
AU1952497A (en) Novel antibody-cytokine fusion protein, and methods of making and using the same
WO2001085961A3 (en) Human caspase-12
AU2002334781A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU6774198A (en) Human rab protein, srab
WO2000077179A3 (en) Human poly(adp-ribose) polymerase 2 materials and methods
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
EP0887416A3 (en) Human AFC1
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002072611A8 (en) Novel human egf-family proteins and polynucleotides encoding the same
WO2000053628A3 (en) Genes encoding human potassium channel proteins
AU5300999A (en) Novel protein, gene encoding the same and utilization thereof
WO2001042297A3 (en) Clasp-3 transmembrane protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002792325

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005266

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003549513

Country of ref document: JP

Ref document number: 2469151

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20028242793

Country of ref document: CN

Ref document number: 1020047008572

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004/05247

Country of ref document: ZA

Ref document number: 200405247

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002357784

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004119961

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2002792325

Country of ref document: EP